Share on LinkedInShare on LinkedIn

ARTICLE · 08 JULY 2013

Supreme Court Subjects Reverse Payment Settlements To Antitrust Review

In a recent opinion with powerful implications for drug manufacturers, the U.S. Supreme Court decided in FTC v. Actavis that reverse payment settlement agreements can violate the antitrust laws despite the antitrust immunity provided by patents and public policy favoring settlement.

United StatesAntitrust/Competition Law

In a recent opinion with powerful implications for drug manufacturers, the U.S. Supreme Court decided in FTC v. Actavis that reverse payment settlement agreements can violate the antitrust laws despite the antitrust immunity provided by patents and public policy favoring settlement. Challenges to these settlements – common in the pharmaceutical industry and also known as "pay-for-delay" agreements – will now be assessed under antitrust's rule-of-reason. This decision will likely prompt brand and generic drug manufacturers to rethink the way they resolve litigation related to generic drug manufacturers' market entry. Below we discuss the opinion and its implications, including proposed legislation.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from